Knight Therapeutics Inc
(GUD.TO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Sales | 82,597 | 81,655 | 72,281 | 75,820 | 63,807 |
| Cost of Goods | 41,835 | 44,767 | 41,880 | 37,525 | 31,330 |
| Gross Profit | 40,762 | 36,888 | 30,401 | 38,295 | 32,477 |
| Operating Expenses | 35,129 | 46,034 | 40,335 | 35,959 | 32,793 |
| Operating Income | 5,633 | -9,146 | -9,934 | 2,336 | -316 |
| Interest Expense | 2,791 | 2,293 | 1,479 | 1,717 | 1,111 |
| Other Income | -7,788 | -11,696 | 12,264 | 17 | -20,885 |
| Pre-tax Income | -4,946 | -23,135 | 851 | 636 | -22,312 |
| Income Tax | -1,009 | -7,947 | -740 | -1,880 | -3,501 |
| Net Income Continuous | -3,937 | -15,188 | 1,591 | 2,516 | -18,811 |
| Net Income | $-3,937 | $-15,188 | $1,591 | $2,516 | $-18,811 |
| EPS Basic Total Ops | -0.04 | -0.13 | 0.01 | 0.02 | -0.16 |
| EPS Basic Continuous Ops | -0.04 | -0.13 | 0.01 | 0.02 | -0.16 |
| EPS Diluted Total Ops | -0.04 | -0.13 | 0.01 | 0.02 | -0.16 |
| EPS Diluted Continuous Ops | -0.04 | -0.13 | 0.01 | 0.02 | -0.16 |
| EBITDA(a) | $10,928 | $-648 | $17,598 | $16,131 | $-7,820 |